BridgeBio Pharma
BBIO
Market cap $8.66B

45.62 USD

-0.70

1.51%

At close Jul 30, 4:00 PM EDT

After hours

45.52

-0.10

0.22%

1 day

-1.51%

5 days

-0.96%

1 month

5.65%

3 months

18.93%

6 months

26.83%

Year to date

61.77%

1 year

75.87%

5 years

53.55%

10 years

65.59%

About: BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

Employees: 730

Healthcare Biotechnology

0

Funds holding %

of 7,323 funds

0

Analysts bullish %

of 12 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

489% more call options, than puts

Call options by funds: $472M | Put options by funds: $80.1M

147% more first-time investments, than exits

New positions opened: 74 | Existing positions closed: 30

53% more repeat investments, than reductions

Existing positions increased: 119 | Existing positions reduced: 78

32% more capital invested

Capital invested by funds: $4.85B [Q4 2024] → $6.41B (+$1.56B) [Q1 2025]

20% more funds holding in top 10

Funds holding in top 10: 15 [Q4 2024] → 18 (+3) [Q1 2025]

15% more funds holding

Funds holding: 262 [Q4 2024] → 302 (+40) [Q1 2025]

3.88% more ownership

Funds ownership: 93.48% [Q4 2024] → 97.36% (+3.88%) [Q1 2025]

See Fund Rankings

Research analyst outlook

12 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$49

7%

upside

Avg. target

$66

44%

upside

High target

$95

108%

upside

12 analyst ratings

12 positive

100%

0 neutral

0%

0 negative

0%

Cantor Fitzgerald Josh Schimmer	108%upside $95	Overweight Reiterated	29 Jul 2025
Truist Securities Danielle Brill	45%upside $66	Buy Initiated	21 Jul 2025
Piper Sandler Biren Amin	49%upside $68	Overweight Maintained	14 Jul 2025
Jefferies Andrew Tsai	53%upside $70	Buy Initiated	14 Jul 2025
Citigroup David Lebowitz	47%upside $67	Buy Maintained	11 Jul 2025

See Analyst Rankings

Financial journalist opinion

Based on 6 articles about BBIO published over the past 30 days

Biotech Has Been Stalling. 3 Stocks That Could See Healthy Gains.

The biotech sector is facing a pivotal moment, after a frustrating year of stalled rallies.

Biotech Has Been Stalling. 3 Stocks That Could See Healthy Gains.

Zacks Investment Research

BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: Should You Buy?

BridgeBio Pharma (BBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: Should You Buy?

Novel Human Genetics Evidence Confirms Estimates of Genetic Prevalence, Underdiagnosis, and Potentially Greater Symptom Burden of Gain-of-Function CASR Variants Associated with ADH1

- By examining over 100 unique variants associated with the CASR gene causative of ADH1, the average frequency of gain-of-function CASR variants was ~3.7 per 100,000, closely aligned to previously published estimates 1 (3.9 per 100,000), which equates to approximately 25,000 carriers of ADH1-causing variants in the US and EU

Novel Human Genetics Evidence Confirms Estimates of Genetic Prevalence, Underdiagnosis, and Potentially Greater Symptom Burden of Gain-of-Function CASR Variants Associated with ADH1

BridgeBio to Host Second Quarter 2025 Financial Results Conference Call on Tuesday, August 5, 2025 at 4:30 pm ET

PALO ALTO, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that it will release its second quarter financial results and business updates after the market closes on Tuesday, August 5, 2025. BridgeBio will host a conference call to discuss the financial results and program updates at 4:30 pm ET the same day.

BridgeBio to Host Second Quarter 2025 Financial Results Conference Call on Tuesday, August 5, 2025 at 4:30 pm ET

CNBC Television

It is time for a move higher in biotech, says Mizuho's Jared Holz

Jared Holz, Mizuho, joins 'Closing Bell Overtime' to discuss if the biotech sector is ready for a breakout.

It is time for a move higher in biotech, says Mizuho's Jared Holz

BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA® European Royalty

PALO ALTO, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced it has sold a portion of royalties due to the Company from sales of BEYONTTRA in Europe to HealthCare Royalty (“HCRx”) and funds managed by Blue Owl Capital (“Blue Owl”) for $300 million. This royalty financing agreement monetizes select anticipated royalties and provides immediate less-dilutive capital to the Company.

BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA® European Royalty

BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET

PALO ALTO, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced the Company will host an investor webinar on Friday, July 11, 2025 at 8:00 am ET with Matthew Wicklund, M.D., FAAN, Professor of Neurology and Vice Chair for Research, Department of Neurology at the University of Texas (UT) Health Science Center San Antonio.

BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET

BridgeBio: New Data Bolsters The Bull Case

BridgeBio's Attruby launch crushed expectations, with Q1 revenue triple analyst estimates, driven by higher-than-expected conversion rates and minimal free trial usage. Competitive threats from Amvuttra appear overstated, as Attruby script declines were minor and BridgeBio management remains confident in market positioning and pricing. My updated model projects 2025 revenues of $728 million, far above consensus, and sees potential for nearly $1 billion in 2026 from existing patients alone.

BridgeBio: New Data Bolsters The Bull Case

BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

PALO ALTO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 in Miami, FL on Monday, June 9 at 8:40 am ET.

BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM

- In a post-hoc analysis of ATTRibute-CM, acoramidis reduced the annual frequency of CVH due to AF/AFL by 43% compared to placebo and reduced the incidence of new-onset AF/AFL by 17% in the subgroup with no prior history of AF compared to placebo

Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM

See News Rankings

Charts implemented using Lightweight Charts™